Prøve GULL - Gratis

INCUBATORS IGNITING BIOSCIENCE ECOSYSTEM

BioSpectrum Asia

|

September 2022

Incubators and accelerators are driving small and medium enterprises (SMEs) in Asia through the development of novel therapeutics and encouraging innovations and commercialisation. Biotechnology incubators provide a stimulating environment that attracts investors, talent, and companies to collaborate on research, thereby fostering industry growth. While the appetite for laboratory space is constantly growing among biotech ventures, countries in the Asia Pacific (APAC) region are actively investing to construct life science hubs that foster innovation strategies and strengthen R&D capabilities. Let’s explore prominent startup incubators and accelerators in key APAC economies that are cultivating biotech innovations to create unicorns.

- Hithaishi C Bhaskar

INCUBATORS IGNITING BIOSCIENCE ECOSYSTEM

The development of innovative clinical therapeutics involves a complex transition from drug discovery to clinical trials to manufacturing and marketing. The APAC region is experiencing an increase in the demand for R&D facilities which can incubate innovative startup ideas in a cost-effective space. In national interest, state-maintained incubators are offering infrastructure and R&D facilities to meet the high specifications while maintaining environmental standards and biosafety requirements. Many early-stage R&D and late-stage therapeutics developments are supported by government funding and initiatives, which incubate research endeavours before they become commercially viable. Further, Accelerators can reinforce the incubator through mentoring and network-building opportunities to propel the startup’s growth and strengthen its value proposition.

The governments in the APAC region are making efforts to promote biotechnology activities in their countries by setting up biotechnology parks, incubators, as well as pilot projects through public-private partnerships. The gradual emergence of co-labs and incubator programmes strengthens R&D capability while governments facilitate financial and tax incentives to foster a startup ecosystem. In addition to providing experimental space and equipment, personnel exchange and support programmes help researchers translationally advance their ideas, to help spin out businesses. In short, incubators are crucial avenues to unlock the commercial value of startups through commercialisation.

FLERE HISTORIER FRA BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

Kyorin and Lunatus partner to launch Lasvic tablets in 9 Middle Eastern countries

Japan's Kyorin Pharmaceutical has entered into an exclusive distribution agreement with Lunatus Marketing & Consulting FZCO for Lasvic tablets (Lascufloxacin hydrochloride).

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Biotium launches GlycoLiner Cell Surface Glycoprotein Labeling Kits

US-based Biotium, a leading innovator in fluorescent dyes and life science reagents, has announced the launch of GlycoLiner Cell Surface Glycoprotein Labeling Kits for rapid, selective, and covalent labeling of cell surface glycoproteins.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Vaxxas appoints former Merck Global Vaccines President David Peacock as CEO

Australia-based Vaxxas has announced the appointment of global biopharmaceutical executive David Peacock as Chief Executive Officer (CEO) to lead the commercialisation of the company's proprietary high-density microarray patch (HD-MAP) vaccination technology.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Thermo Fisher partners with NVIDIA leveraging AI to advance scientific instrumentation

US-based Thermo Fisher Scientific Inc. has announced a strategic collaboration with NVIDIA to power artificial intelligence (AI)based solutions and laboratory automation at scale.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Bruker consolidates ownership of TOFWERK in expansion of mass spectrometry portfolio

Bruker Corporation has announced the acquisition of an additional 60 per cent ownership stake in TOFWERK AG, a Switzerland-based innovator in ultra-fast time-of-flight (TOF) mass spectrometry technology for small molecule applied markets, consolidating Bruker's ownership to 100 per cent.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

Bioengineered tissue by Japan emerges as revolutionary treatment for secondary lymphedema

A research team led by Associate Professor Kosuke Kusamori from the Faculty of Pharmaceutical Sciences at Tokyo University of Science (TUS), Japan, is pioneering an innovative technique for lymphatic tissue engineering that could revolutionize the treatment of secondary lymphedema.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

Chitose and Fujifilm Biosciences to drive global innovation and biopharma manufacturing

Japan-based Chitose Laboratory Corp. & Fujifilm Biosciences Inc. have announced a new strategic alliance that leverages the strengths of both companies in advancing biopharmaceutical production.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Vibrant Therapeutics on-boards Dr Han Lee as Co-CEO

Vibrant Therapeutics, a clinical-stage biotechnology company based in China and US, has announced the appointment of Dr Han Lee as co-chief executive officer (CEO).

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

IIT-D and AIIMS develop swallowable microdevice for microbiome study

Researchers at the Indian Institute of Technology (IIT) Delhi, and All India Institute of Medical Sciences (AIIMS) have developed an ingestible device that can sample bacteria directly from the small intestine, opening a new window into the human gut microbiome.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Ambitious research to develop multivalent vaccines against multiple deadly filoviruses

Scientists at the University of Oxford, in collaboration with partners, will spearhead the development of new vaccines that aim to provide comprehensive protection against multiple lethal filoviruses, including Ebola virus, Sudan virus, Bundibugyo virus, and Marburg virus.

time to read

1 min

BioSpectrum Asia Feb 2026

Translate

Share

-
+

Change font size